BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21615375)

  • 1. Platelet transfusions for patients with haematological malignancies: who needs them?
    Estcourt LJ; Stanworth SJ; Murphy MF
    Br J Haematol; 2011 Aug; 154(4):425-40. PubMed ID: 21615375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
    Stanworth SJ; Hyde C; Brunskill S; Murphy MF
    Br J Haematol; 2005 Dec; 131(5):588-95. PubMed ID: 16351634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
    Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
    Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia.
    Apelseth TO; Hervig T; Bruserud O
    Blood Rev; 2011 May; 25(3):113-22. PubMed ID: 21316823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic platelet transfusions: should they be a treatment of the past?
    Zeller MP; Al-Habsi KS; Heddle NM
    Curr Opin Hematol; 2014 Nov; 21(6):521-7. PubMed ID: 25203535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with prophylactic platelet transfusion trigger in haematological patients.
    Eikenboom JC; van Wordragen R; Brand A
    Transfus Med; 2005 Feb; 15(1):45-8. PubMed ID: 15713128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients.
    Slichter SJ
    J Clin Apher; 2006 Apr; 21(1):78-84. PubMed ID: 16619231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia and platelet transfusions in patients with cancer.
    Valent J; Schiffer CA
    Cancer Treat Res; 2011; 157():251-65. PubMed ID: 21052961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.
    Stanworth SJ; Hyde C; Heddle N; Rebulla P; Brunskill S; Murphy MF
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004269. PubMed ID: 15495093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
    Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
    Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials.
    Cid J; Lozano M
    Transfusion; 2007 Mar; 47(3):464-70. PubMed ID: 17319827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.
    Nevo S; Fuller AK; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 May; 47(5):801-12. PubMed ID: 17465944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An audit of platelet transfusion within the Wellington Cancer Centre.
    Buhrkuhl DC; Karlsson MK; Carter JM
    Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing platelet transfusion therapy.
    Heal JM; Blumberg N
    Blood Rev; 2004 Sep; 18(3):149-65. PubMed ID: 15183900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
    Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT; Winton EF; Khoury HJ
    Cancer; 2013 Nov; 119(21):3784-7. PubMed ID: 23921838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet transfusion goals in oncology patients.
    Fasano RM; Josephson CD
    Hematology Am Soc Hematol Educ Program; 2015; 2015():462-70. PubMed ID: 26637759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
    Stanworth SJ; Dyer C; Choo L; Bakrania L; Copplestone A; Llewelyn C; Norfolk D; Powter G; Littlewood T; Wood EM; Murphy MF;
    Transfus Med Rev; 2010 Jul; 24(3):163-71. PubMed ID: 20656185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions to reduce platelet prophylactic transfusions in patients with hypoproliferative thrombocytopenia: providing patients with the full benefit.
    Vamvakas EC; Hitzler WE
    Clin Lab; 2013; 59(5-6):459-64. PubMed ID: 23865342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals.
    Karakatsanis SJ; Papadatos SS; Syrigos KN
    Hosp Pract (1995); 2019 Feb; 47(1):16-23. PubMed ID: 30409035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.